Key result
A standardized protocol using multi-electrode array systems and iPS cell-derived cardiomyocytes was established to evaluate QT prolongation and proarrhythmic potentials in drug development.
Population
Human induced pluripotent stem cell-derived cardiomyocytes (iPS-CMs)
Design
Preclinical
Authors
Loading...
Standardized iPS-CM MEA protocol may improve preclinical cardiac safety screening; leaves open clinical translation and regulatory adoption.
A standardized MEA protocol for iPS-CMs provides a reproducible in vitro assay system for assessing the proarrhythmic risk of drug candidates.
Kanda et al. (2016) studied Cardiac safety in drug development. Multi-electrode array (MEA) system using iPS cell-derived cardiomyocytes was evaluated. A standardized protocol using multi-electrode array systems and iPS cell-derived cardiomyocytes was established to evaluate QT prolongation and proarrhythmic potentials in drug development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: